Ultragenyx Pharmaceutical INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Ultragenyx Pharmaceutical Inc. files its 10-K report, showcasing its commitment to rare disease treatments and pipeline advancements.
NASDAQ
10-K: Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan: Restricted Stock Unit Agreement for Directors
Ultragenyx Pharmaceutical Inc. grants restricted stock units to directors, outlining the terms and conditions under its 2023 Incentive Plan.